StockDuty ← Dashboard Aug 18, 2026 03:26 PM ET
CatalystGeopolitics

NRX TARGETS 2026 KETAFREE APPROVAL AND OUTLINES SPARC-TMS TRIAL IN 400 PATIENTS BACKED BY MILITARY FUNDING - SEEKINGALPHA

2026 approval catalyst and 400-patient trial with military funding.

What changed
2026 approval catalyst and 400-patient trial with military funding.
Why it matters
2026 approval catalyst and 400-patient trial with military funding. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
Zelenskyy signals surprise at Trump claim of Russia-Ukraine ‘energy ceasefire’ but would back it if Moscow does – as it →BOND YIELDS JUMP, OIL EXTENDS GAINS AS US-IRAN CEASEFIRE EXPIRES →RUSSIA RULES OUT IMMEDIATE UKRAINE CEASEFIRE →